126.73 0.00 (0.00%)
After hours: 5:15PM EDT
|Bid||124.01 x 900|
|Ask||135.92 x 800|
|Day's Range||125.43 - 131.60|
|52 Week Range||122.49 - 178.86|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||1.56 (1.18%)|
|1y Target Est||149.07|
Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
SAN FRANCISCO (AP) — San Francisco has come to be known around the world as a place for aggressive panhandling, open-air drug use and sprawling tent camps, the dirt and despair all the more remarkable for the city's immense wealth.
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.
McKesson Corporation (MCK) will release financial results for its second fiscal quarter ended September 30, 2018 on Thursday, October 25, 2018, prior to the opening of trading on the New York Stock Exchange. The company has scheduled a conference call for 8:00 AM Eastern Time (5:00 AM Pacific Time), during which John Hammergren, chairman and chief executive officer, and Britt Vitalone, executive vice president and chief financial officer, will review these results. Craig Mercer, senior vice president, Investor Relations is the leader of the call and the password is ‘McKesson’.
Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp, has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said on Wednesday. The move comes after McKesson Chief Executive John Hammergren said in January that he intended to take Change Healthcare public. Tapping underwriters shows that McKesson is gearing up for the IPO, which the sources said is expected to take place in the first half of 2019.
Overall, healthcare valuations have slightly risen to a price/fair value of 1.07, up from 0.98 at the end of the second quarter and 1.04 at the start of the year, but the differences in industry valuations continue to suggest drug, biotech, and drug supply chain industries are the most undervalued areas. Innovative new drug launches combined with strong advancements in drug pipelines are supporting a steady growth outlook for the drug and biotech industries. Concerns around U.S. governmental reforms addressing drug pricing appear to be easing on the valuations for drug manufacturers with the majority of reform concerns still surrounding potential changes to the drug supply chain.
Henry Schein (HSIC) generated revenues of $3.33 billion in the second quarter, compared to revenues of $3.06 billion in the second quarter of 2017. For fiscal 2018 and 2019, the company is expected to generate revenues of $13.41 billion and $14.05 billion, respectively, compared with revenues of $12.46 billion in fiscal 2017.
Investors pursuing a solid, dependable stock investment can often be led to McKesson Corporation (NYSE:MCK), a large-cap worth US$26.33b. Market participants who are conscious of risk tend to search forRead More...
McKesson Corporation (MCK) today announced that its Board of Directors has elected Dominic Caruso as a new independent director, effective September 12, 2018. With the election of Dominic Caruso, McKesson’s Board of Directors increases from eight to nine members, eight of whom are independent. “Dominic’s three decades of global financial and operational experience, leadership, and tenure in the healthcare industry make him an ideal addition to our Board of Directors,” said John H. Hammergren, chairman and chief executive officer, McKesson Corporation.
After a downward trend for the stock price in 2018, investors may consider adding Cardinal Health (NYSE:CAH) stock to their portfolio for the rest of the year. There are several long strategies in CAH stock that could lead to impressive profits. The healthcare services and medical supplier Cardinal Health has paid handsome dividends over the past years with a current dividend yield of 3.6%.
According to GuruFocus list of 52-week lows, these guru stocks have reached their 52-week lows. The price of Philip Morris International Inc. (PM) shares has declined to close to the 52-week low of $78.79, which is 36.2% off the 52-week high of $119.43. The company has a market cap of $122.48 billion.
Seth Klarman (Trades, Portfolio), considered a master of value investing, has two stocks in his portfolio that investors can purchase at relatively low prices. Warning! GuruFocus has detected 2 Warning Signs with MCK. Speaking to MIT's Sloan Investment Club in 2007, Klarman said his Boston-based Baupost Group, which manages about $30 billion, made money in 24 of the past 25 years.
McKesson Corporation (MCK) announced that Britt Vitalone, the company’s executive vice president and chief financial officer, will present at the Morgan Stanley Global Healthcare Conference in New York at 10:30 a.m. ET on Friday, September 14, 2018. A complete listing of upcoming events for the investment community is available on the company’s Investor Relations website. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.
McKesson Corporation (MCK) today announced that Brian S. Tyler, Ph.D., has been appointed president and chief operating officer, McKesson Corporation, effective August 2, 2018. Tyler will report to John Hammergren, chairman and chief executive officer, and will become a member of the executive committee. “Brian is ideally suited to lead McKesson’s global operations based on his deep industry knowledge, outstanding track record as a business leader, and his commitment to operational excellence and customer success,” said Hammergren.
Drugmakers are tapping the brakes on price increases. For McKesson Corp. investors, that could mean lost sales. If pharmaceutical companies continue to put off plans to raise prices amid pressure from the Trump administration, that could threaten San Francisco-based McKesson’s bottom line.